NCT00282971

Brief Summary

To assess the impact on glucose control by inhaled insulin in patients with type 2 diabetes who are not well controlled on 2 or more oral anti-diabetic agents

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
354

participants targeted

Target at P25-P50 for phase_3 diabetes-mellitus-type-2

Timeline
Completed

Started Mar 2006

Typical duration for phase_3 diabetes-mellitus-type-2

Geographic Reach
7 countries

64 active sites

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 26, 2006

Completed
1 day until next milestone

First Posted

Study publicly available on registry

January 27, 2006

Completed
1 month until next milestone

Study Start

First participant enrolled

March 6, 2006

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 19, 2008

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 19, 2008

Completed
1.5 years until next milestone

Results Posted

Study results publicly available

August 26, 2009

Completed
Last Updated

April 2, 2019

Status Verified

April 1, 2019

Enrollment Period

2 years

First QC Date

January 26, 2006

Results QC Date

February 11, 2009

Last Update Submit

April 1, 2019

Conditions

Keywords

Type 2 diabetes melllitus

Outcome Measures

Primary Outcomes (1)

  • Percentage Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24

    \[(week 24 value - baseline value)/baseline value\]\*100%

    4, 12 and 24 weeks

Secondary Outcomes (2)

  • Percentage of Participants Achieving Glycemic Control by Visit

    4, 12 and 24 weeks

  • Change From Baseline in FEV1 at Week 24 LOCF

    24 weeks

Study Arms (2)

Inhaled Insulin

EXPERIMENTAL

Inhaled insulin plus oral therapy

Drug: Inhaled Insulin (Exubera)

Standard of Care

OTHER

Standard of Care: All licensed diabetes drugs can be prescribed per discretion of investigators

Other: Standard of Care

Interventions

Addition of inhaled insulin to pre-existing oral diabetes therapy.

Inhaled Insulin

Standard of Care: All licensed diabetes drugs can be prescribed per discretion of investigators

Standard of Care

Eligibility Criteria

Age35 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Diabetes mellitus type 2
  • Failing two or more oral anti-diabetic agents

You may not qualify if:

  • Asthma, COPD
  • Smoking

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (64)

Gain Medical Center

Coquitlam, British Columbia, V3K 3P4, Canada

Location

Misericordia Health Centre

Winnipeg, Manitoba, R3C 1A2, Canada

Location

Maritime Research Center

Bathurst, New Brunswick, E2A 4X7, Canada

Location

Office of Dr. Salim Sunderji

London, Ontario, N6P 1A9, Canada

Location

Orillia Soldier's Memorial Hospital

Orillia, Ontario, L3V 2Z6, Canada

Location

Douglas Tweel M.D. Professional Corporation

Charlottetown, Prince Edward Island, C1A 1L2, Canada

Location

Laboratoire Sante Le Gaspesien Inc.

Bonaventure, Quebec, G0C 1E0, Canada

Location

Centre de santé et de services sociaux de Chicoutimi, Centre de médecine genique communataire

Chicoutimi, Quebec, G7H 5H6, Canada

Location

Rhodin Recherche Clinique

Drummondville, Quebec, J2B 1H8, Canada

Location

Q & T Research Outaouais Inc.

Gatineau, Quebec, J8Y 6S9, Canada

Location

Hopital Charles LeMoyne

Greenfield Park, Quebec, J4V2H1, Canada

Location

Hopital Laval

Saint-Foy, Quebec, G1V 4G5, Canada

Location

Centre Medical des Carrieres

Saint-Marc-des-Carrieres, Quebec, G0A 4B0, Canada

Location

CIC Mauricie Inc.

Trois-Rivières, Quebec, G8T 7A1, Canada

Location

Hotel Dieu CHU, Clinique d´Endocrinologie, Maladie Metaboliques, Nutrition

Nantes, Cedex 01, F-44035, France

Location

Groupe Hospitalier Sud/Service d'Endocrinologie

Amiens, 80094, France

Location

Private Practise

Armentières, 59427, France

Location

Service d'Endocrinologie-

Bondy, 93143, France

Location

Hopital LA Cavale Blanche, Service de Diabetologie

Brest, 29609, France

Location

CHU Cote de Nacre, Service d'Endocrinologie

Cean Cedex, 14033, France

Location

Private Practise

Chartres, 28000, France

Location

Office of Antoine Lemaire, MD

Lille, 59000, France

Location

Centre Hospitalier Bretagne Sud

Lorient, 56322, France

Location

Hopital Lapeyronnie Sce des Maladies

Montpellier, 34295, France

Location

Hopital Saint Michel

Paris, 75015, France

Location

Hopital Bichat, Service d'Endocrinology

Paris, 75877, France

Location

Hopital Robert Debre

Reims, 51100, France

Location

C.H. Sud, Diabetologie

Rennes, 35056, France

Location

Centre Hospitalier Victor Provo

Roubaix, 59100, France

Location

Hôpital Jeanne d'Arc - Dommartin les Toul

Toul, 54201, France

Location

General Hospital of Athens "Laikon", 1st Propedeutic University Internal Medicine Clinic

Athens, 11527, Greece

Location

"Hygeia" Diagnostic and Therapeutic Center of Athens, Diabetes Clinic

Athens, 151 23, Greece

Location

"ATTIKON" University General Hospital, 2nd Propedeutic University Internal Medicine Clinic

Haidari, 124 62, Greece

Location

Peripheral General Hospital of Nikaia "Ag. Panteleimon", Internal Medicine Department

Pireaus, 18454, Greece

Location

University General Hospital of Thessaloniki "A.H.E.P.A." 1st Propedeutic University Internal Medicin

Thessaloniki, 546 36, Greece

Location

Hospital Infante D. Pedro

Aveiro, 3814-096, Portugal

Location

Hospitais da Universidade de Coimbra

Coimbra, 3000-075, Portugal

Location

Associação Protectora dos Diabéticos de Portugal

Lisbon, 1250-203, Portugal

Location

Serviço de Endocrinologia - Hospital de Egas Moniz

Lisbon, 1300, Portugal

Location

Hospital Geral de Santo António

Porto, 4099-001, Portugal

Location

Centro Hospitalar de Torres Vedras

Torres Vedras, 2560-324, Portugal

Location

Hospital Clinico Universitario de Santiago

Santiago de Compostela, A Coruña, 15706, Spain

Location

Hospital de Conxo

Santiago de Compostela, A Coruña, 15706, Spain

Location

Hospital de Bellvitge

L'Hospitalet de Llobregat, Barcelona, 08907, Spain

Location

Hospital Mutua de Terrassa

Terrassa, Barcelona, 08221, Spain

Location

Clinica Universitaria de Navarra

Pamplona, Navarre, 31008, Spain

Location

Hospital Universitario Central de Asturias

Oviedo, Principality of Asturias, 33006, Spain

Location

Hospital General Universitario de Alicante

Alicante, 03010, Spain

Location

Hospital de La Santa Creu I Sant Pau

Barcelona, 08025, Spain

Location

Hospital General Universitario Valle de Hebron

Barcelona, 08035, Spain

Location

Hospital Universitario Puerta de Hierro

Madrid, 28035, Spain

Location

Hospital 12 de Octubre

Madrid, 28041, Spain

Location

Hospital de Mostoles

Madrid, 28935, Spain

Location

Complejo Hospitalario Carlos Haya Hospital Civil - Pabellon C

Málaga, 29009, Spain

Location

Hospital Montecelo

Pontevedra, 36071, Spain

Location

Hospital Universitario La Fe

Valencia, 46009, Spain

Location

Hospital Clinico Universitario de Valencia

Valencia, 46010, Spain

Location

Hospital Clinico Universitario Lozano Blesa

Zaragoza, 50009, Spain

Location

Ängelholms sjukhus

Ängelholm, 262 81, Sweden

Location

Sodersjukhuset

Stockholm, 118 83, Sweden

Location

Karolinska US Huddinge

Stockholm, 141 86, Sweden

Location

Hacettepe University Medical School Department of Endocrinology

Ankara, Turkey (Türkiye)

Location

Istanbul University Istanbul Medical School, Department of Endocrinology

Istanbul, 34390, Turkey (Türkiye)

Location

Dokuz Eylul University Medical School, Department of Endocrinology

Izmir, 35340, Turkey (Türkiye)

Location

Related Links

MeSH Terms

Conditions

Diabetes Mellitus, Type 2

Interventions

ExuberaStandard of Care

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System Diseases

Intervention Hierarchy (Ancestors)

Quality Indicators, Health CareQuality of Health CareHealth Services AdministrationHealth Care Quality, Access, and Evaluation

Limitations and Caveats

Study terminated prematurely since the sponsor stopped marketing and manufacturing of EXUBERA and withdrew Market Authorization in Europe in September 2008. No efficacy, safety, or quality reason was associated with the premature halt of this study.

Results Point of Contact

Title
Pfizer ClinicalTrials.gov Call Center
Organization
Pfizer, Inc.

Study Officials

  • Pfizer CT.gov Call Center

    Pfizer

    STUDY DIRECTOR

Publication Agreements

PI is Sponsor Employee
No
Restriction Type
OTHER
Restrictive Agreement
Yes

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 26, 2006

First Posted

January 27, 2006

Study Start

March 6, 2006

Primary Completion

February 19, 2008

Study Completion

February 19, 2008

Last Updated

April 2, 2019

Results First Posted

August 26, 2009

Record last verified: 2019-04

Locations